Novel Signatures for Immunotherapies beyond PD-1 & PD-L1 capturing insights on spatial metabolism of tumor and lymphyocytes
Discovery of differentiated and multi-scale biomarkers to add actionable insights
Novel image based signatures to predict response at a voxel level going beyond traditional metrics
Trial design, analysis, and expansion; including patient selection, synthetic control arms, experimental vs. SoC benefit assessment
Test multiple drug scenarios in thousands of patient tumors, capturing morphology, microenvironment, spatial metabolism at a fraction of the time/cost of traditional studies
Most of us have experienced the pain of a friend or family member’s cancer diagnosis and treatment in our lives. The process of diagnosis, treatment and monitoring — and the resulting uncertainty — has a debilitating impact. At SimBioSys, we…
Abstract: What would you do if you knew everything about a patient’s tumor? How should a physician make a treatment decision with multi-omics and imaging data at single-cell resolution? We sought to answer these questions by constructing a deterministic, 4-D,…
Abstract: Metabolism is an important regulator of cancer behavior. The extent to which patient-to-patient variability in tumor metabolism influences patient prognosis, however, remains unclear. We addressed this question by developing an approach to simulate cancer metabolism that integrates RNA-seq data…
Background: Despite substantial advances in the understanding of breast cancer biology, the decision to use NACT for EBC is based on tumor size, lymph node status, and subtype. Even with aggressive therapy, the majority of women will not achieve a pathologic…
John Cole, Co-Founder & Chief Scientific Officer of Research Park startup SimBioSys, joins the podcast! He discusses the breakthroughs his team has created for “transforming decision making and patient experience in cancer care” through a powerful software platform. Tune in…
SOLUTIONS
- TumorSight Viz
- TumorSight RISK
- PhenoScope
RESOURCES
©SimBioSys